CoChat

Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease

Open access
Lenders, Malte, Stypmann, Jörg, Duning, Thomas, Schmitz, Boris, Brand, Stefan-Martin, Brand, Eva · 2016 · Journal of the American Society of Nephrology

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Fabry disease (FD) is a progressive multisystemic disorder, treatable with recombinant enzyme replacement therapy (agalsidase). However, recent studies suggest an endogenous inhibition of agalsidase in patients with FD, as reported for other lysosomal storage diseases. To assess the clinical consequences of serum-mediated agalsidase inhibition in affected patients, we determined the agalsidase inhibition status of 168 patients (68 male) with FD and compared outcomes of inhibition-positive patients with those of inhibition-negative patients. The assessment included clinical events during time on agalsidase, determination of renal and cardiac function, and evaluation of FD-related symptoms. The frequency of serum-mediated agalsidase inhibition was 40% in agalsidase-treated males. Inhibition did not depend on the compound initially used (agalsidase-α or -β). Agalsidase inhibition was associated with higher lyso-globotriaosylceramide levels and worse disease severity scores in patients. Compared with agalsidase inhibition-negative men, agalsidase inhibition-positive men showed greater left ventricular mass (P=0.02) and substantially lower renal function (difference in eGFR of about -30 ml/min per 1.73 m(2); P=0.04), which was confirmed by a longitudinal 5-year retrospective analysis. Additionally, affected patients presented more often with FD-typical symptoms, such as diarrhea, fatigue, and neuropathic pain, among others. Therefore, patients with poor clinical outcome on agalsidase should be tested for agalsidase inhibition. Future studies are warranted to determine if affected patients with FD benefit from acute reduction of anti-agalsidase antibodies or long-term immune modulation therapies to suppress agalsidase inhibition and to identify mechanisms that minimize antibody generation against agalsidase.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2014121226

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 133

Metadata

Authors
Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E.
Affiliations
University Hospital Münster (DE)
Corresponding author
  • Lenders, Malte
  • Brand, Eva
Venue
Journal of the American Society of Nephrology
Published
2016-01
Volume
27
Issue
1
Pages
256-264
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2129050348
Cited by
133
References
27
Citations by year
2026: 9 · 2025: 8 · 2024: 14 · 2023: 15 · 2022: 13 · 2021: 10 · 2020: 18 · 2019: 7 · 2018: 18 · 2017: 9 · 2016: 9
FWCI
9.58
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Society of Nephrology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
Fabry disease, enzyme replacement therapy, anti-enzyme antibodies, left ventricular mass, renal function, disease severity, lysosomal storage disease, neuropathic pain, immunomodulation
MeSH terms
Adult, alpha-Galactosidase, Fabry Disease, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Failure, Enzyme Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease. https://app.cochat.ai/papers/10.1681/asn.2014121226
The paper
Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E. (2016). Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2014121226

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.